Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol in chronic heart failure
RBR-9z6dw6bPhase 2Not yet recruiting
- Sponsor
- INCOR
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in chronic heart failure (CHF), heart failure with reduced ejection fraction (HFrEF) and left ventricular systolic dysfunction (LVSD) comparing Cannabidiol with Placebo (2 arms). Planned start Mar 2022; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
chronic heart failure (CHF)heart failure with reduced ejection fraction (HFrEF)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on RBR-9z6dw6b.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-9z6dw6b.